problems concealing sleep sleed disorders
Conditions
Interventions
None listed
Sponsors
Bioprojet
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1. Signed informed consent prior to any study-mandated procedure. 2. Healthy male subjects aged between 18 and 45 years (inclusive). 3. Subjects with a body weight of at least 50 kg and a body mass index (BMI) between 18.0 and 28.0 kg/m2 (both inclusive). 4. Healthy subjects, based on history, physical examination, complete laboratory evaluation, and 12-lead ECG. 5. Normal arterial blood pressure (BP) and pulse rate or, if abnormal, considered not clinically significant by the investigator. Normal BP to be [100-140] mmHg systolic and [45-90] mmHg diastolic. Normal pulse rate to be [40-90] bpm after 5 minutes rest in lying position. 6. Ability to communicate well with the investigator in the local language, and to understand and comply with the requirements of the study.
Exclusion criteria
Exclusion criteria: 1.Subject with a history of cardiovascular, pulmonary, gastro-intestinal, hepatic, renal, metabolic, haematological, neurological, psychiatric, systemic, or infectious disease, or any other condition which, in the opinion of the investigator, would jeopardize the safety of the subject, or impact the validity of the study results. 2. Previous history of fainting, collapse, syncope, orthostatic hypotension, or vasovagal reactions. 3. Haematology, clinical chemistry, and urinalysis results deviating from the normal range to a clinically relevant extent at screening. 4. Clinically significant findings on physical examination at screening. 5. 12-lead electrocardiogram (ECG) with clinically relevant abnormalities in supine position at screening. 6. Positive results from urine drug screen at screening. 7. Veins unsuitable for i.v. puncture on either arm (e.g., veins that are difficult to locate, access or puncture, or veins with a tendency for rupture during or after puncture). 8. Treatment with any prescribed medications (including vaccines) or over-the-counter (OTC) medications (including herbal medicines such as St John*s Wort) within 2 weeks prior to the (first) scheduled administration of study drug, except paracetamol (maximum 1 g/day). 9. Treatment with another investigational drug within 3 months prior to screening or having participated in more than four investigational drug studies within 1 year prior to screening. 10. History or clinical evidence of alcoholism or drug abuse within the 3-year period prior to screening. 11. History or clinical evidence of any disease, and/or existence of any surgical or medical condition, which might interfere with the absorption, distribution, metabolism or excretion of the study drugs. 12. Have undergone surgery or have donated an amount equal or more than 500 mL blood, or 300 mL of plasma, within 3 months prior to screening. 13. Positive results from any of the hepatitis serology tests (HBsAg, anti-HCV), at screening. 14. Positive results from the HIV 1 or/and 2 serology at screening. 15. History of allergy to diphenhydramine or antihistaminic drugs. 16. Smoking more than 5 cigarettes per day.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Study Part 1 : Single Ascending Dose Part. The safety tolerability criteria include the following analysis: • Adverse and unexpected events, emergent or not, reported during the study course (frequency, severity, relationship to study drug, incidence and occurrence) and up to one month after the last dose taken. • Change of vital signs parameters (heart rate, blood pressure, respiratory rate, and body temperature) from baseline values. • Physical examination: abnormalities in each system class and change from baseline • Laboratory abnormalities and change from baseline. • ECG parameters performed at each predetermined time point during the study days; change from baseline. • 48-hour ECG Holter recording, significant change from baseline. Study Part 2 : Proof Of Concept Part. • Polysomnography in comparison with placebo and active control. | — |
Secondary
| Measure | Time frame |
|---|---|
| Study Part 1 : Single Ascending Dose Part. The following pharmacokinetic parameters will be assessed: • Serum levels and urine levels of oxathridine and of its major inactive methylated metabolite (BP1.5658). • Time to reach the maximum serum concentration (Tmax). • Maximum serum concentration (Cmax). • Area under the serum concentration-time curve (AUCt) for the last sampling time and area under the serum concentration-time curve from time zero to time of infinity (AUC0-*). • Terminal half-life (T1/2β). • Amount of oxathridine and of its major inactive methylated metabolite (BP1.5658) excreted in urine (Ae and fe). • Renal clearance (CLr) • Apparent volume of distribution in steady state(Vss) and in the terminal elimination phase (Vz) The following pharmacodynamic tests will be performed : • Saccadic eye movements • Smooth pursuit eye movements • Body sway • Visual analogue scales (VAS) according to Bond and Lader • Visual analogue scales (VAS) Bowdle • Visual Verbal Learning Test • EEG • Sustained Attention to Response Task (SART) • Leeds Sleep Evaluation Questionnaire (LSEQ). | — |
Countries
Netherlands
Outcome results
None listed